Global Velcade Market Size By Type (1.0 Mg Injection, 3.5 Mg Injection), By Application (Multiple Myeloma, Mantle Cell Lymphoma), By Region, And Segment Forecasts, 2023 to 2032

The Global Velcade Market was valued at USD 1.7 billion in 2023 and is projected to reach USD 2.8 billion by 2031, growing at a CAGR of 6.3% during the forecast period of 2023–2031. Velcade (bortezomib) is a proteasome inhibitor widely used in the treatment of multiple myeloma and mantle cell lymphoma. The market's growth is primarily driven by the increasing prevalence of hematologic malignancies, expanding oncology research, and the rising global geriatric population prone to cancer-related complications. Additionally, the integration of Velcade in combination therapy regimens and its inclusion in various national cancer treatment guidelines further bolster its demand.

Drivers:

1. Rising Prevalence of Multiple Myeloma and Lymphoma:

Globally, multiple myeloma continues to be one of the leading hematologic cancers, particularly affecting the aging population. Velcade remains a cornerstone in first-line and relapsed treatment regimens, fueling consistent demand.

2. Expanding Use in Combination Therapies:

Velcade’s efficacy significantly improves when used alongside other agents such as lenalidomide, dexamethasone, and monoclonal antibodies. This positions it as a preferred component in modern combination regimens, enhancing its commercial potential.

3. Advancements in Cancer Diagnosis and Screening:

Improved screening methods and rising awareness about early diagnosis have led to more patients being identified in treatable stages, which drives the need for effective therapeutics like Velcade.

Restraints:

1. Patent Expiry and Generic Competition:

The expiration of Velcade’s patents in several key markets has opened the door for generic bortezomib products, significantly impacting the brand’s market share and pricing power.

2. Side Effects and Toxicity Concerns:

Despite its efficacy, Velcade is associated with notable adverse effects such as peripheral neuropathy and gastrointestinal toxicity, which can limit its use in certain patient populations.

Opportunity:

1. Market Penetration in Developing Economies:

Emerging markets such as Latin America, Southeast Asia, and parts of Africa present untapped opportunities due to improving healthcare infrastructure and increased investment in oncology care.

2. Clinical Trials for New Indications:

Ongoing research into Velcade’s utility beyond multiple myeloma and mantle cell lymphoma, including in solid tumors and autoimmune diseases, opens new avenues for market expansion.

Market by System Type Insights:

By system type, Injectable Bortezomib dominated the market in 2023, driven by its established role in hospital and outpatient oncology settings. Subcutaneous injection is preferred over intravenous delivery due to reduced side effects, which has encouraged further adoption.

Market by End-use Insights:

Hospitals and Cancer Treatment Centers emerged as the largest end-use segment in 2023. These settings are primary treatment venues for hematologic cancers and are typically equipped to handle the administration and monitoring of cytotoxic drugs like Velcade. Meanwhile, Specialty Clinics and Ambulatory Infusion Centers are witnessing rapid growth due to rising outpatient oncology care trends.

Market by Regional Insights:

North America led the global Velcade market in 2023, supported by advanced healthcare infrastructure, high awareness levels, and robust reimbursement frameworks. Asia-Pacific is expected to register the highest CAGR during the forecast period, driven by increasing cancer burden, government initiatives in cancer care, and improving access to oncology drugs in countries like China and India.

Competitive Scenario:

Key players in the global Velcade market include Takeda Pharmaceutical Company Ltd., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories, Fresenius Kabi, and Sun Pharmaceutical Industries Ltd. These companies are investing in biosimilar development, expanding production capabilities, and forming strategic alliances to maintain competitiveness. For instance:

In 2023, Dr. Reddy’s launched its generic version of bortezomib in multiple countries post-patent expiry, capturing significant market share.

In 2024, Takeda initiated trials exploring novel Velcade combinations for front-line therapy in early-stage multiple myeloma patients.

Scope of Work – Global Velcade Market

Report Metric Details

Market Size (2023) USD 1.7 Billion

Projected Market Size (2031) USD 2.8 Billion

CAGR (2023–2031) 6.3%

Market Segments By System Type (Injectable, Oral), By End-Use (Hospitals, Clinics)

Growth Drivers Rising cancer prevalence, expanding combination therapy use, early diagnosis

Opportunities Emerging markets, new clinical indications, generic expansion

Key Market Developments:

2023: Takeda Pharmaceuticals continued to lead the market with post-marketing studies evaluating Velcade's long-term safety in combination regimens.

2024: Fresenius Kabi expanded its oncology portfolio by launching a biosimilar version of bortezomib in Latin America.

2025: Sun Pharma secured approval for its Velcade generic in multiple Southeast Asian markets, accelerating regional competition.

FAQs:

1) What is the current market size of the Global Velcade Market?

The market size in 2023 was valued at USD 1.7 billion.

2) What is the major growth driver of the Global Velcade Market?

The increasing prevalence of hematologic cancers, especially multiple myeloma and lymphoma, is the primary growth driver.

3) Which is the largest region during the forecast period in the Global Velcade Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to witness the highest growth.

4) Which segment accounted for the largest market share in the Global Velcade Market?

Injectable bortezomib held the largest market share by system type, and hospitals led by end-use.

5) Who are the key market players in the Global Velcade Market?

Key players include Takeda Pharmaceutical Company Ltd., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories, Fresenius Kabi, and Sun Pharmaceutical Industries Ltd.